Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on July 1, 2007

Papers In Press, published online ahead of print April 24, 2007
J. Lipid Res., doi:10.1194/jlr.M700097-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M700097-JLR200v1
48/7/1607    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yan, W.
Right arrow Articles by Ogden, M. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yan, W.
Right arrow Articles by Ogden, M. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on February 22, 2007
Revised on March 30, 2007
Accepted on April 23, 2007

Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS

Weiying Yan, Gary D. Byrd, and Michael W. Ogden

Human Studies Division, R. J. Reynolds Tobacco Co., Winston Salem, NC

Corresponding Author: byrdg{at}rjrt.com

A simple, rapid LC-MS/MS method was developed to identify and quantitate in human urine the isoprostanes iPF2a-III, 15-epi-iPF2a-III, iPF2a-VI, and 8,12-iso-iPF2a-VI along with the prostaglandin PGF2a and 2,3-dinor-iPF2a-III, a metabolite of iPF2a-III. Assay specificity, linearity, precision, and accuracy met the required criteria for most analytes. The urine sample storage stability and standard solution stability were also tested. The methodology was applied to analyze 24-hour urine samples collected from smokers and nonsmokers on controlled diets. The results for iPF2a-III obtained by our method were significantly correlated with results by an enzyme-linked immunosorbent assay (ELISA), although an approximate 2-fold high bias was observed for the ELISA data. For iPF2a-III and its metabolite 2,3-dinor-iPF2a-III, smokers had significantly higher concentrations than nonsmokers (513 ± 275 versus 294 ± 104 pg/mg creatinine; 3030 ± 1546 versus 2046 ± 836 pg/mg creatinine, respectively). Concentration of iPF2a-VI tended to be higher in smokers than in nonsmokers; however, the increase was not statistically significant in this sample set. Concentrations of the other three isoprostane isomers showed no trends towards difference between smokers and nonsmokers. Among smokers, the daily output of two type VI isoprostanes showed a weak correlation with the amount of tobacco smoke exposure as determined by urinary excretion of total nicotine equivalents.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 jvdiHome page
C. Soffler, V. L. Campbell, and D. M. Hassel
Measurement of urinary F2-isoprostanes as markers of in vivo lipid peroxidation: a comparison of enzyme immunoassays with gas chromatography-mass spectrometry in domestic animal species
J Vet Diagn Invest, March 1, 2010; 22(2): 200 - 209.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement